KIT mutation and AHN-associated oncogenic profiles in systemic mastocytosis with an associated hematological neoplasm
Authors:
- Paula Navarro-NavarroPNPaula Navarro-Navarro
- Carlos Maria Fernandez GimenezCGCarlos Maria Fernandez Gimenez
- Iván Álvarez-TwoseIÁIván Álvarez-Twose
- Laura Sánchez-MuñozLSLaura Sánchez-Muñoz
- Ana HenriquesAHAna Henriques
- Alba Pérez-PonsAPAlba Pérez-Pons
- María González-TablasMGMaría González-Tablas
- Maria GonzalezMGMaria Gonzalez
- Sergio MatarrazSMSergio Matarraz
Open Access
- 16 June 2026
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (17) , 5916-5931
Abstract
In 5-15% of systemic mastocytosis (SM) patients, SM coexists with another associated hematological neoplasm (AHN). Most SM-AHN patients harbor a KIT-mutation, mainly KIT p.D816V, together with other AHN-related genetic alterations; however, limited data exists about the frequency and the clinical impact of the coexistence of both types of genetic alterations in the same vs. distinct bone marrow (BM) cell compartments. Here we analyzed 79 SM-AHN patients classified into cases who: i) displayed distinct unrelated genetic alterations in BM mast cells (MC) and AHN cells (21/79, 27%); ii) shared the KIT-mutation as a first genetic event (24/79, 30%) involving both BM MC and AHN cells, together with or without AHN-associated alterations restricted to the latter cells; iii) patients presenting with AHN-associated alterations as a first event (25/79, 32%) present in both BM MC and AHN cells, and; iv) patients in whom both alterations involved virtually all SM and AHN cells (9/79, 11%). Overall, patients with genetically unrelated SM and AHN more frequently showed clinical manifestations associated with SM (ie. anaphylaxis, osteoporosis and skin lesions) together with prolonged progression-free survival (PFS), while those cases with shared genetic alterations displayed signs of more advanced disease (ie. cytopenias or organomegalies) and shorter PFS and overall survival. Our findings confirm the clinical, genetic and prognostic heterogeneity of SM-AHN and point out its association with the underlying oncogenic profile of neoplastic MC and AHN cells.Keywords
This publication has 76 references indexed in Scilit:
- A case of high‐risk AML in a patient with advanced systemic mastocytosisClinical Case Reports, 2023
- Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and managementAmerican Journal of Hematology, 2023
- Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosisGenes, Chromosomes and Cancer, 2018
- Systemic mastocytosis with associated clonal hematological non‐mast cell lineage disease: Clinical significance and comparison of chomosomal abnormalities in SM and AHNMD componentsAmerican Journal of Hematology, 2012
- Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: Reference patterns for age‐related changes and disease‐induced shiftsCytometry Part B: Clinical Cytometry, 2004
- Systemic mastocytosis with associated clonal hematological non‐mast‐cell lineage disease: Analysis of clinicopathologic features and activating c‐kit mutationsAmerican Journal of Hematology, 2003
- Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemiaCancer, 2003
- Incidence of numerical chromosome aberrations in meningioma tumors as revealed by fluorescence in situ hybridization using 10 chromosome‐specific probesCytometry, 2002
- Mast cell disease associated with acute myeloid leukemia: Detection of a newc-kit mutation Asp816HisAmerican Journal of Hematology, 2000
- Significance of systemic mast cell disease with associated hematologic disordersCancer, 1988